Literature DB >> 23174991

Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.

A C Liwa1, H S Schaaf, B Rosenkranz, H I Seifart, A H Diacon, P R Donald.   

Abstract

There are no paediatric data regarding slow-release para-aminosalicylic acid (PAS). We studied PAS plasma concentrations in 10 children receiving a single 150 mg/kg dose daily or 75 mg/kg twice daily and 12 adults receiving 4 g twice daily. Blood specimens pre-dose and 2, 4, 6, 8 and 12 h post-dose from the children and 2, 3, 4, 5, 6, 8 and 12 h post-dose from the adults were analysed by high performance liquid chromatography MS/MS. The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587). No parameters differed significantly between children and adults nor between the two doses in the same children. A 150 mg/kg PAS dosage given as one or two daily doses leads to plasma concentrations in children similar to those of adults receiving 4 g PAS twice daily.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23174991     DOI: 10.1093/tropej/fms053

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  10 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

Review 2.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

4.  N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Authors:  Sherwin K B Sy; Lizanne de Kock; Andreas H Diacon; Cedric J Werely; Huiming Xia; Bernd Rosenkranz; Lize van der Merwe; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

5.  Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.

Authors:  Yves Kibleur; Hervé Brochart; Hendrik S Schaaf; Andre H Diacon; Peter R Donald
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

6.  Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.

Authors:  Sang-In Park; Jaeseong Oh; Kyungho Jang; Jangsoo Yoon; Seol Ju Moon; Jong Sun Park; Jae Ho Lee; Junghan Song; In-Jin Jang; Kyung-Sang Yu; Jae-Yong Chung
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

7.  Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

Authors:  Anneke C Hesseling; Paolo Denti; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Maxwell Chirehwa; Jana L Winckler; Jun Mao; Heather R Draper; Lubbe Wiesner; Jennifer Norman; Helen McIlleron; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2022-05-04       Impact factor: 5.938

Review 8.  Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.

Authors:  James A Seddon; H Simon Schaaf
Journal:  Pneumonia (Nathan)       Date:  2016-11-24

Review 9.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

10.  Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Authors:  Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.